Zur Kurzanzeige

2019-04-02Zeitschriftenartikel DOI: 10.25646/6162
Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology
dc.contributor.authorvon Berg, Laura
dc.contributor.authorStern, Daniel
dc.contributor.authorPauly, Diana
dc.contributor.authorMahrhold, Stefan
dc.contributor.authorWeisemann, Jasmin
dc.contributor.authorJentsch, Lisa
dc.contributor.authorHansbauer, Eva-Maria
dc.contributor.authorMüller, Christian
dc.contributor.authorAvondet, Marc A.
dc.contributor.authorRummel, Andreas
dc.contributor.authorDorner, Martin B.
dc.contributor.authorDorner, Brigitte G.
dc.date.accessioned2019-05-28T08:37:42Z
dc.date.available2019-05-28T08:37:42Z
dc.date.issued2019-04-02none
dc.identifier.other10.1038/s41598-019-41722-z
dc.identifier.urihttp://edoc.rki.de/176904/6189
dc.description.abstractBotulinum neurotoxins (BoNTs) are the most potent toxins known and cause the life threatening disease botulism. Sensitive and broad detection is extremely challenging due to the toxins’ high potency and molecular heterogeneity with several serotypes and more than 40 subtypes. The toxicity of BoNT is mediated by enzymatic cleavage of different synaptic proteins involved in neurotransmitter release at serotype-specific cleavage sites. Hence, active BoNTs can be monitored and distinguished in vitro by detecting their substrate cleavage products. In this work, we developed a comprehensive panel of monoclonal neoepitope antibodies (Neo-mAbs) highly specific for the newly generated N- and/or C-termini of the substrate cleavage products of BoNT serotypes A to F. The Neo-mAbs were implemented in a set of three enzymatic assays for the simultaneous detection of two BoNT serotypes each by monitoring substrate cleavage on colour-coded magnetic Luminex-beads. For the first time, all relevant serotypes could be detected in parallel by a routine in vitro activity assay in spiked serum and food samples yielding excellent detection limits in the range of the mouse bioassay or better (0.3–80 pg/mL). Therefore, this work represents a major step towards the replacement of the mouse bioassay for botulism diagnostics.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleFunctional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technologynone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6189-5
dc.identifier.doihttp://dx.doi.org/10.25646/6162
dc.type.versionpublishedVersionnone
local.edoc.container-titleScientific Reportsnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.nature.com/articles/s41598-019-41722-z#Abs1none
local.edoc.container-publisher-nameNature Publishing Groupnone
local.edoc.container-volume9none
local.edoc.container-issue5531none
local.edoc.container-reportyear2019none
local.edoc.container-year2019none
local.edoc.container-firstpage1none
local.edoc.container-lastpage14none
local.edoc.rki-departmentInfektionsepidemiologienone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige